BeiGene Past Earnings Performance
Past criteria checks 0/6
BeiGene has been growing earnings at an average annual rate of 1.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 44.9% per year.
Key information
1.3%
Earnings growth rate
11.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 44.9% |
| Return on equity | -24.8% |
| Net Margin | -25.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
Dec 01BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
Nov 06BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Revenue & Expenses Breakdown
How BeiGene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 23,508 | -5,993 | 12,221 | 13,464 |
| 30 Jun 24 | 22,504 | -3,806 | 12,013 | 13,534 |
| 31 Mar 24 | 19,948 | -5,664 | 11,583 | 13,218 |
| 31 Dec 23 | 17,452 | -6,258 | 10,684 | 12,624 |
| 30 Sep 23 | 15,649 | -7,128 | 10,238 | 21,148 |
| 30 Jun 23 | 13,139 | -12,570 | 9,985 | 17,935 |
| 31 Mar 23 | 10,694 | -13,166 | 9,014 | 14,072 |
| 31 Dec 22 | 9,766 | -13,820 | 8,819 | 11,315 |
| 30 Sep 22 | 8,892 | -15,291 | 8,943 | 0 |
| 30 Jun 22 | 7,160 | -13,600 | 8,062 | 0 |
| 31 Mar 22 | 5,561 | -12,424 | 7,001 | 0 |
| 31 Dec 21 | 7,475 | -9,264 | 6,292 | 9,273 |
| 30 Sep 21 | 6,851 | -8,641 | 5,751 | 0 |
| 30 Jun 21 | 6,115 | -8,569 | 5,059 | 0 |
| 31 Mar 21 | 5,653 | -7,645 | 4,424 | 0 |
| 31 Dec 20 | 2,016 | -10,608 | 3,918 | 0 |
| 30 Sep 20 | 1,804 | -10,268 | 3,635 | 0 |
| 30 Jun 20 | 1,588 | -9,852 | 3,388 | 0 |
| 31 Mar 20 | 2,850 | -8,108 | 3,100 | 0 |
| 31 Dec 19 | 2,982 | -6,605 | 2,703 | 0 |
| 30 Sep 19 | 3,073 | -5,923 | 2,268 | 0 |
| 30 Jun 19 | 2,980 | -4,570 | 1,794 | 0 |
| 31 Mar 19 | 1,634 | -4,945 | 1,504 | 0 |
| 31 Dec 18 | 1,363 | -4,635 | 1,344 | 0 |
| 30 Sep 18 | 1,083 | -3,468 | 1,032 | 0 |
| 30 Jun 18 | 2,143 | -1,611 | 775 | 0 |
| 31 Mar 18 | 1,700 | -923 | 519 | 0 |
| 31 Dec 17 | 1,551 | -606 | 407 | 0 |
| 30 Sep 17 | 1,465 | -209 | 290 | -34 |
| 30 Jun 17 | 0 | -1,249 | 221 | 0 |
| 31 Mar 17 | 3 | -1,018 | 177 | 0 |
| 31 Dec 16 | 7 | -828 | 140 | 0 |
| 30 Sep 16 | 38 | -726 | 98 | 35 |
| 30 Jun 16 | 47 | -581 | 80 | 0 |
| 31 Mar 16 | 52 | -445 | 60 | 0 |
| 31 Dec 15 | 57 | -371 | 47 | 0 |
| 30 Sep 15 | 35 | -214 | 38 | 0 |
| 30 Jun 15 | 66 | -182 | 48 | 0 |
| 31 Mar 15 | 73 | -162 | 45 | 0 |
| 31 Dec 14 | 81 | -113 | 43 | 0 |
| 31 Dec 13 | 67 | -45 | 19 | 0 |
Quality Earnings: BGNE is currently unprofitable.
Growing Profit Margin: BGNE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BGNE is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BGNE has a negative Return on Equity (-24.79%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:58 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BeiGene, Ltd. is covered by 57 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Michael Meng | BOCI Research Ltd. |
| Yonglin Yan | BOCI Research Ltd. |